Full-Time
Warehouse Associate 1
Updated on 9/4/2026
Bio-Rad Laboratories
5,001-10,000 employees
Life science reagents, instruments, software
Compensation Overview
$17.02 - $23.37/hr
Woodinville, WA, USA
In Person
Must be within commuting distance of the Woodinville office.
 Warehouse & Fulfillment (2) |
|---|
| , |
Get referred to Bio-Rad Laboratories
See people who can refer or advise you
- A high school diploma or equivalent is required.
- Shipping and receiving experience is preferred.
- Ability to utilize a computer and accompanying software for customer order processing, spreadsheet, and word processing applications is required.
- Ability to lift 50 pounds is required.
- Ability to perform detailed work and multitask with organizational skills is required.
- Experience in a manufacturing environment with perishable products is preferred.
- Employees must wear safety shoes that meet or exceed the ASTM F2413 standard for protective footwear.
- Build boxes, pick orders, pack orders, ship through the enterprise resource planning system, perform cycle counting, and complete other assigned duties.
- Work within multiple warehouse functions, including receiving, picking and packing, staging, and shipping.
- Prepare domestic and international goods for shipment.
- Operate motorized and non-motorized equipment to move materials, parts, supplies, and equipment as instructed.
- Assist with physical inventory cycle counts.
- Shipping and receiving experience.
- Experience in a manufacturing environment with perishable products.
Bio-Rad Laboratories, Inc. develops, manufactures, and sells a wide range of tools for life science research and clinical diagnostics, including reagents, instruments, and software. The company serves universities, pharmaceutical and biotech firms, and clinical laboratories, providing products that support cell biology, gene expression, protein purification, and imaging. Its products are sold through a dedicated direct sales force and online channels, with revenue from product sales and service contracts. The company emphasizes quality and reliability in its offerings. The main difference from competitors is its broad, integrated portfolio of end-to-end solutions across research and clinical applications, combined with a global sales and support network. Bio-Rad’s goal is to help researchers and clinicians advance scientific discoveries and improve patient outcomes by enabling accurate experiments and dependable diagnostics.
Company Size
5,001-10,000
Company Stage
IPO
Headquarters
Hercules, California
Founded
1952
Get referred to Bio-Rad Laboratories
See people who can refer or advise you
Simplify's Take
What believers are saying
- September 1, 2026 Foresight Pro Nuvia columns extend Bio-Rad into biomanufacturing.
- Bio-Rad launched QX700-compatible Vericheck kits for cell therapy QC in 2026.
- Q2 2026 ddPCR instrument revenue grew over 20%, signaling platform traction.
What critics are saying
- Life Science sales fell 4.1% in Q2 2026, still pressuring core research demand.
- Elliott built a 2026 stake and presses management while Schwartz family controls votes.
- Caltech's 2025 patent suit targets Droplet multiplexing and threatens QX700 injunctions by 2027.
What makes Bio-Rad Laboratories unique
- Bio-Rad spans Life Science and Clinical Diagnostics, reducing dependence on one market.
- QX700 ddPCR and Vericheck kits target high-value biopharma quality-control workflows.
- Foresight Pro columns use single-lot Nuvia packing, a rare standardized chromatography offer.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Fertility Treatment Support
Life Insurance
Disability Insurance
Parental Leave
Employee Stock Purchase Plan
Wellness Program
Health Savings Account/Flexible Spending Account
Professional Development Budget
Student Loan Assistance
Pet Insurance
Paid Vacation
Employee Resource Groups
Growth & Insights and Company News
6 month growth
↑ 1%1 year growth
↑ 1%2 year growth
↑ 3%Bio-Rad expands Foresight Pro prepacked chromatography Columns with Nuvia ion exchange and mixed-mode resins for biomanufacturing. Extended Range of Process-Scale Columns Prepacked with CEX, AEX, CEX-HIC, and AEX-HIC Chromatography Resins Provides an Effective Solution for Purification of Biomolecules in Downstream Processing HERCULES, Calif. - September 01, 2026 - Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the launch of prepacked process-scale Foresight(TM) Pro chromatography columns packed with Bio-Rad's scalable Nuvia(TM) chromatography resins, for downstream process-scale chromatography applications throughout the various stages in biological drug development and manufacturing. The extended range includes columns packed with anion exchangers (AEX) Nuvia Q Media and Nuvia HP-Q Media, cation exchanger (CEX) Nuvia HR-S Media, and mixed-mode (MM) resins Nuvia cPrime Media, a CEX-hydrophobic interaction chromatography (CEX-HIC) resin, and Nuvia aPrime 4A Media, an AEX-HIC chromatography resin. These options expand the existing family of Foresight Pro columns packed with CHT(TM) Ceramic Hydroxyapatite Media Type I, Type II, and XT, which have been incorporated into various regulatory-approved processes worldwide. Columns prepacked with Nuvia resins are now available with internal diameters (ID) of 5 to 13 cm and bed heights of 10 and 20 cm. Columns with IDs of 20 to 45 cm are also in development with anticipated availability in early 2027. Nuvia chromatography resins use Bio-Rad's Nuvia bead technology, featuring a polyacrylamide (acrylamide polymer) base bead suitable for laboratory-scale purification, process development, pilot-scale production, and commercial biomanufacturing applications. Bio-Rad's Nuvia resins are designed to have minimal non-specific binding reactions, due to the hydrophilic nature of the bead polymer, and maintain a constant dynamic binding capacity over a wide range of flow rates. The Nuvia bead allows for fast mass transfer and is chemically and mechanically stable over a wide range of conditions. All Bio-Rad Foresight Pro Columns are manufactured in a controlled ISO Class 7 cleanroom, providing good manufacturing practice (GMP) ready columns. The prepacked columns' standardized design and format can provide a more cost-effective and flexible solution than customer-packed columns, and columns are available in a range of diameters and bed volumes. "The new Nuvia prepacked Foresight Pro chromatography columns build on the strong market response to our original CHT Ceramic Hydroxyapatite Media columns, which launched in 2022," said Diab Elmashni, Director, Process Chromatography Business at Bio-Rad Laboratories. "Customers asked us for column options built around different resins, and this line is our response. What sets these columns apart is that each one is packed using media from a single production lot, instead of blending multiple resin batches together during packing. That single-lot approach is what makes our Foresight Pro Columns a genuinely unique, single-source offering, providing biopharma customers with superior technical, application, and product support." BIO-RAD, NUVIA, CHT, and FORESIGHT are trademarks of Bio-Rad Laboratories, Inc. in certain jurisdictions. The Foresight Pro Column hardware design is covered by U.S. Patent Number 11,841,350 and foreign counterparts. Nuvia aPrime 4A Media is covered by U.S. Patent Numbers 9,669,402 and 10,682,640, and foreign counterparts. Nuvia cPrime Media is covered by U.S. Patent Numbers 9,309,282, 10,792,654, and 11,590,486, and foreign counterparts.
Danaher Corporation reported Q2 2026 revenue of $6.3 billion, up 5.5% year-over-year, with adjusted diluted EPS rising 8% to $1.94. The company raised its full-year adjusted EPS guidance to $8.45–$8.60, driven by Life Sciences strength and mid-teens bioprocessing order growth. However, Danaher's bioprocessing unit missed expectations, signalling continued softness in biopharma demand. The news sent shares of Sartorius AG lower, which in turn affected Bio-Rad Laboratories, which holds a $5 billion stake in Sartorius. Bio-Rad shares fell about 1% in early trading. Bio-Rad reported Q2 net sales of $651 million, flat year-over-year. Its Life Science segment declined 4.1% to $252 million due to academic funding constraints. On 31 July, Bio-Rad announced a restructuring plan involving headcount reductions and facility closures, expecting $80 million to $90 million in pre-tax charges.
Bio-Rad Laboratories reported sequential revenue growth of 10% in Q2 2026, recovering from first-quarter challenges. However, year-over-year performance remained pressured by academic research softness and biopharma caution. The company's Digital PCR (ddPCR) instrument revenue grew over 20%, driven by competitive wins and the integration of Stilla Technologies. Clinical Diagnostics returned to growth, led by quality controls and blood typing. Bio-Rad reaffirmed full-year currency-neutral revenue guidance of -3% to +0.5%. The company announced a multi-year restructuring programme targeting $30 million to $35 million in net annual savings by 2027, with 40 to 50 basis points of expected margin expansion next year. Management cited a $4 million headwind in China and Middle East volatility affecting global freight costs as ongoing challenges.
Bio-Rad Laboratories reported second-quarter earnings of $2.62 per share, beating the Zacks Consensus Estimate of $2.34 per share by nearly 12%. This marks only the second time in four quarters the medical products company has surpassed earnings expectations. However, revenue of $651 million for the quarter ended June 2026 fell slightly short of estimates by 0.97%, though the company has topped revenue forecasts in three of the past four quarters. Year-ago revenue was $651.6 million. Bio-Rad shares have gained 10.5% year-to-date, slightly underperforming the S&P 500's 11% rise. The company currently holds a Zacks Rank of Hold, suggesting shares should perform in line with the market.
Bio-Rad Laboratories (NYSE:BIO) releases earnings results, beats estimates by $0.87 EPS. August 4, 2026 Key points. * Bio-Rad beat quarterly expectations: The company reported EPS of $2.62, exceeding the $1.75 consensus by $0.87, while revenue reached $651 million versus estimates of $623.99 million. * Shares declined despite the earnings beat: BIO fell $1.84 to $332.87, though it remained near its 12-month high of $343.12 and above both its 50-day and 200-day moving averages. * Analyst sentiment remains cautious: Bio-Rad has an average "Reduce" rating and a consensus price target of $303.33, while institutional investors own 65.24% of the company. * Five stocks we like better than Bio-Rad Laboratories. Bio-Rad Laboratories (NYSE:BIO - Get Free Report) released its earnings results on Tuesday. The medical research company reported $2.62 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.75 by $0.87, FiscalAI reports. Bio-Rad Laboratories had a return on equity of 3.56% and a net margin of 6.52%.The business had revenue of $651.00 million for the quarter, compared to analyst estimates of $623.99 million. Bio-Rad Laboratories price performance. BIO stock traded down $1.84 on Tuesday, reaching $332.87. 263,909 shares of the company's stock were exchanged, compared to its average volume of 329,369. The stock has a fifty day moving average of $300.29 and a 200-day moving average of $287.70. The firm has a market cap of $8.91 billion, a PE ratio of 54.84 and a beta of 1.06. The company has a quick ratio of 2.37, a current ratio of 3.21 and a debt-to-equity ratio of 0.12. Bio-Rad Laboratories has a twelve month low of $236.73 and a twelve month high of $343.12. Institutional investors weigh in on Bio-Rad Laboratories. Institutional investors have recently made changes to their positions in the stock. Geneos Wealth Management Inc. increased its holdings in shares of Bio-Rad Laboratories by 115.2% in the 2nd quarter. Geneos Wealth Management Inc. now owns 142 shares of the medical research company's stock valued at $34,000 after purchasing an additional 76 shares in the last quarter. Los Angeles Capital Management LLC acquired a new position in Bio-Rad Laboratories during the fourth quarter worth about $47,000. Itau Unibanco Holding S.A. increased its holdings in Bio-Rad Laboratories by 57.6% in the fourth quarter. Itau Unibanco Holding S.A. now owns 197 shares of the medical research company's stock valued at $60,000 after buying an additional 72 shares in the last quarter. State of Wyoming acquired a new stake in shares of Bio-Rad Laboratories in the 4th quarter worth approximately $74,000. Finally, Quarry LP increased its stake in Bio-Rad Laboratories by 131.5% in the 3rd quarter. Quarry LP now owns 287 shares of the medical research company's stock valued at $80,000 after purchasing an additional 163 shares in the last quarter. 65.24% of the stock is currently owned by hedge funds and other institutional investors. Wall Street analysts forecast growth. A number of equities analysts recently weighed in on BIO shares. Zacks Research lowered shares of Bio-Rad Laboratories from a "hold" rating to a "strong sell" rating in a research report on Monday, July 13th. Wells Fargo & Company reduced their target price on shares of Bio-Rad Laboratories from $320.00 to $290.00 and set an "equal weight" rating for the company in a research note on Friday, May 1st. Royal Bank Of Canada began coverage on shares of Bio-Rad Laboratories in a report on Friday, May 15th. They issued an "outperform" rating and a $320.00 target price on the stock. Citigroup lowered shares of Bio-Rad Laboratories from a "buy" rating to a "neutral" rating and dropped their price target for the stock from $375.00 to $300.00 in a research note on Tuesday, April 7th. Finally, Weiss Ratings cut shares of Bio-Rad Laboratories from a "sell (d+)" rating to a "sell (d)" rating in a report on Wednesday, May 6th. One investment analyst has rated the stock with a Buy rating, two have issued a Hold rating and two have given a Sell rating to the company's stock. According to data from MarketBeat.com, Bio-Rad Laboratories presently has an average rating of "Reduce" and a consensus target price of $303.33. Discover more MarketBeat Research Tools text messages MarketBeat All Access Bio-Rad Laboratories company profile. Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories. Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions. Further reading. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Bio-Rad Laboratories, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bio-Rad Laboratories wasn't on the list. While Bio-Rad Laboratories currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys. With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.